Urolithin A During Bedrest in Older Adults
This study will determine whether oral urolithin A (UA) attenuates the loss of knee-extensor strength caused by 10 days of horizontal bed rest in older adults.
Обзор исследования
Статус
Статус
Условия
Условия
Вмешательство/лечение
Вмешательство/лечение
Подробное описание
The randomized comparison will also assess muscle mass, cardiorespiratory fitness, physical performance and glucose tolerance, together with cellular mechanisms of muscle adaptation. Orthostatic tolerance, balance responses to galvanic vestibular stimulation (GVS), salivary cortisol, and oral and fecal microbiome profiles will provide complementary exploratory measures of adaptation and recovery.v
Тип исследования
Тип исследования
Регистрация (Оцененный)
Регистрация
Фаза
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
Контакты исследования
- Имя: Sharmila Research Coordinator Baccalaureate Nurse
- Номер телефона: 1+514-984-9975
- Электронная почта: reachlab@muhc.mcgill.ca
Учебное резервное копирование контактов
- Имя: Guy Hajj Boutros
- Номер телефона: 514-501-9975
- Электронная почта: reachlab@muhc.mcgill.ca
Критерии участия
Критерии приемлемости
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Men and women at least 65 years of age at enrolment, with a recruitment target of equal numbers of each sex
- English or French speaking
- Females not of childbearing potential
- Willing to maintain current lifestyle and dietary habits, including level of physical activity, allowed medication/supplements habits for the duration of the study
- Physically inactive, defined for eligibility as reporting no more than 2.5 hours of moderate-to-vigorous physical activity per week.
Exclusion Criteria:
- Participated in a clinical trial within 90 days of screening or more than 4 times in the previous year.
- Neuropsychological condition and/or cognitive impairment that, in the QI's opinion, could interfere with study participation.
- Uncontrolled hypothyroidism or hyperthyroidism. Hypothyroid patients who have changed their dose of hormone replacement therapy in the 6 weeks before screening are not eligible.
- Confirmed rheumatoid arthritis, acquired immunodeficiency syndrome (AIDS), type 1 or type 2 diabetes mellitus.
- History of cancer in the last 6 months.
- On any medications including NHPs/living with medical conditions that would compromise the study outcome or the safety of the research participant. For any supplements deemed acceptable, participants must be on a stable dose of allowed supplements/medications for at least 3 months prior to enrollment. All concomitant therapies will be documented.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Профилактика
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Четырехместный
Количество рук
Оружие и интервенции
Группа участников / АрмияГруппа участников / Армия |
Вмешательство/лечениеВмешательство/лечение |
|---|---|
|
Экспериментальный: Bed rest-Urolithin A group (BR-UA)
Participants in BR-UA group will receive a total of 1,000 mg of UA orally each day. |
1000mg Urolithin A daily
Другие имена:
|
|
Плацебо Компаратор: BR-PLA group (C)
Participants in group "C" will receive matching placebo. |
Placebo |
Что измеряет исследование?
Первичные показатели результатов
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Changes in knee extensor strength using biodex at baseline and following the intervention.
Временное ограничение: Between baseline testing (B2) and after 10 days of bedrest during the recovery period (R3)
|
To determine whether UA supplementation reduces the percentage loss of maximal voluntary isometric knee-extensor strength (N) using Biodex between baseline and recovery, compared with placebo. |
Between baseline testing (B2) and after 10 days of bedrest during the recovery period (R3)
|
|
Changes in V02 using indirect calorimetry at baseline and following the intervention.
Временное ограничение: Between baseline testing (B2) and after 10 days of bedrest during the recovery period (R3)
|
To compare the effects of UA and placebo on cardiorespiratory fitness function using peak oxygen uptake (VO2peak) between baseline and recovery, compared with placebo. |
Between baseline testing (B2) and after 10 days of bedrest during the recovery period (R3)
|
Вторичные показатели результатов
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Changes in body composition using DEXA scan at baseline and following the intervention.
Временное ограничение: Between baseline testing (B1) and after 10 days of bedrest during the recovery period (R3)
|
To determine whether UA supplementation had an effect on changes in fat free mass and fat mass using the DEXA scan between baseline and recovery, compared with placebo. |
Between baseline testing (B1) and after 10 days of bedrest during the recovery period (R3)
|
|
Changes in mitochondrial respiration at baseline and following the intervention.
Временное ограничение: Between baseline testing (B3) and after 10 days of bedrest during the recovery period (R3)
|
To determine whether UA supplementation had an effect on changes in mitochondrial respiration and function using the OROBORUS from muscle biopsy samples between baseline and recovery, compared with placebo. |
Between baseline testing (B3) and after 10 days of bedrest during the recovery period (R3)
|
|
Changes in muscle mass at baseline and following the intervention.
Временное ограничение: Between baseline testing (B3) and after 10 days of bedrest during the recovery period (R2)
|
To determine whether UA supplementation had an effect on changes in muscle mass using CT scan between baseline and recovery, compared with placebo. |
Between baseline testing (B3) and after 10 days of bedrest during the recovery period (R2)
|
Соавторы и исследователи
Спонсор
Спонсор
Следователи
Следователи
- Главный следователь: Jose A Morais, Medical Doctor, McGill University Health Centre/Research Institute of the McGill University Health Centre
Публикации и полезные ссылки
Общие публикации
- Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999 Sep;22(9):1462-70. doi: 10.2337/diacare.22.9.1462.
- Kortebein P, Ferrando A, Lombeida J, Wolfe R, Evans WJ. Effect of 10 days of bed rest on skeletal muscle in healthy older adults. JAMA. 2007 Apr 25;297(16):1772-4. doi: 10.1001/jama.297.16.1772-b. No abstract available.
- Andreux PA, Blanco-Bose W, Ryu D, Burdet F, Ibberson M, Aebischer P, Auwerx J, Singh A, Rinsch C. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab. 2019 Jun;1(6):595-603. doi: 10.1038/s42255-019-0073-4. Epub 2019 Jun 14.
- Utz KS, Korluss K, Schmidt L, Rosenthal A, Oppenlander K, Keller I, Kerkhoff G. Minor adverse effects of galvanic vestibular stimulation in persons with stroke and healthy individuals. Brain Inj. 2011;25(11):1058-69. doi: 10.3109/02699052.2011.607789. Epub 2011 Aug 31.
- Stalder T, Kirschbaum C, Kudielka BM, Adam EK, Pruessner JC, Wust S, Dockray S, Smyth N, Evans P, Hellhammer DH, Miller R, Wetherell MA, Lupien SJ, Clow A. Assessment of the cortisol awakening response: Expert consensus guidelines. Psychoneuroendocrinology. 2016 Jan;63:414-32. doi: 10.1016/j.psyneuen.2015.10.010. Epub 2015 Oct 20.
- Singh A, D'Amico D, Andreux PA, Fouassier AM, Blanco-Bose W, Evans M, Aebischer P, Auwerx J, Rinsch C. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Rep Med. 2022 May 17;3(5):100633. doi: 10.1016/j.xcrm.2022.100633.
- Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022 Dec 13;328(22):2252-2264. doi: 10.1001/jama.2022.21022.
- Hopewell S, Chan AW, Collins GS, Hrobjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025 Apr 14;389:e081123. doi: 10.1136/bmj-2024-081123.
- Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hrobjartsson A. SPIRIT 2025 statement: updated guideline for protocols of randomised trials. BMJ. 2025 Apr 28;389:e081477. doi: 10.1136/bmj-2024-081477.
- Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Social Sciences and Humanities Research Council of Canada. Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. TCPS 2. 2022. https://ethics.gc.ca/eng/policy-politique_tcps2-eptc2_2022.html.
- Health Canada. Notice: Period reduced for keeping clinical trial records for drugs and natural health products. 28 March 2022. https://www.canada.ca/en/health-canada/services/clinical-trials/notice-period-reduced-keeping-records-drugs-natural-health-products.html. Accessed 25 September 2026.
- Mirzayi C, Renson A; Genomic Standards Consortium; Massive Analysis and Quality Control Society; Zohra F, Elsafoury S, Geistlinger L, Kasselman LJ, Eckenrode K, van de Wijgert J, Loughman A, Marques FZ, MacIntyre DA, Arumugam M, Azhar R, Beghini F, Bergstrom K, Bhatt A, Bisanz JE, Braun J, Bravo HC, Buck GA, Bushman F, Casero D, Clarke G, Collado MC, Cotter PD, Cryan JF, Demmer RT, Devkota S, Elinav E, Escobar JS, Fettweis J, Finn RD, Fodor AA, Forslund S, Franke A, Furlanello C, Gilbert J, Grice E, Haibe-Kains B, Handley S, Herd P, Holmes S, Jacobs JP, Karstens L, Knight R, Knights D, Koren O, Kwon DS, Langille M, Lindsay B, McGovern D, McHardy AC, McWeeney S, Mueller NT, Nezi L, Olm M, Palm N, Pasolli E, Raes J, Redinbo MR, Ruhlemann M, Balfour Sartor R, Schloss PD, Schriml L, Segal E, Shardell M, Sharpton T, Smirnova E, Sokol H, Sonnenburg JL, Srinivasan S, Thingholm LB, Turnbaugh PJ, Upadhyay V, Walls RL, Wilmes P, Yamada T, Zeller G, Zhang M, Zhao N, Zhao L, Bao W, Culhane A, Devanarayan V, Dopazo J, Fan X, Fischer M, Jones W, Kusko R, Mason CE, Mercer TR, Sansone SA, Scherer A, Shi L, Thakkar S, Tong W, Wolfinger R, Hunter C, Segata N, Huttenhower C, Dowd JB, Jones HE, Waldron L. Reporting guidelines for human microbiome research: the STORMS checklist. Nat Med. 2021 Nov;27(11):1885-1892. doi: 10.1038/s41591-021-01552-x. Epub 2021 Nov 17.
- Gouspillou G, Sgarioto N, Kapchinsky S, Purves-Smith F, Norris B, Pion CH, Barbat-Artigas S, Lemieux F, Taivassalo T, Morais JA, Aubertin-Leheudre M, Hepple RT. Increased sensitivity to mitochondrial permeability transition and myonuclear translocation of endonuclease G in atrophied muscle of physically active older humans. FASEB J. 2014 Apr;28(4):1621-33. doi: 10.1096/fj.13-242750. Epub 2013 Dec 26.
- Holwerda AM, Paulussen KJM, Overkamp M, Smeets JSJ, Gijsen AP, Goessens JPB, Verdijk LB, van Loon LJC. Daily resistance-type exercise stimulates muscle protein synthesis in vivo in young men. J Appl Physiol (1985). 2018 Jan 1;124(1):66-75. doi: 10.1152/japplphysiol.00610.2017. Epub 2017 Sep 21.
- Cefis M, Marcangeli V, Hammad R, Granet J, Leduc-Gaudet JP, Gaudreau P, Trumpff C, Huang Q, Picard M, Aubertin-Leheudre M, Belanger M, Robitaille R, Morais JA, Gouspillou G. Impact of physical activity on physical function, mitochondrial energetics, ROS production, and Ca2+ handling across the adult lifespan in men. Cell Rep Med. 2025 Feb 18;6(2):101968. doi: 10.1016/j.xcrm.2025.101968. Epub 2025 Feb 10.
- Hajj-Boutros G, Sonjak V, Faust A, Balram S, Lagace JC, St-Martin P, Divsalar DN, Sadeghian F, Liu-Ambrose T, Blaber AP, Dionne IJ, Duchesne S, Kontulainen S, Theou O, Morais JA. Myths and Methodologies: Understanding the health impact of head down bedrest for the benefit of older adults and astronauts. Study protocol of the Canadian Bedrest Study. Exp Physiol. 2024 May;109(5):812-827. doi: 10.1113/EP091473. Epub 2024 Feb 19.
- Cipriani E, et al. Mesurer le genre en recherche sur les humains, un nouveau questionnaire adapté. Unité de Soutien SSA Québec. 2022:1-16.
- Marusic U, Narici M, Simunic B, Pisot R, Ritzmann R. Nonuniform loss of muscle strength and atrophy during bed rest: a systematic review. J Appl Physiol (1985). 2021 Jul 1;131(1):194-206. doi: 10.1152/japplphysiol.00363.2020. Epub 2021 Mar 11.
- Liu S, D'Amico D, Shankland E, Bhayana S, Garcia JM, Aebischer P, Rinsch C, Singh A, Marcinek DJ. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA Netw Open. 2022 Jan 4;5(1):e2144279. doi: 10.1001/jamanetworkopen.2021.44279.
- Ryu D, Mouchiroud L, Andreux PA, Katsyuba E, Moullan N, Nicolet-Dit-Felix AA, Williams EG, Jha P, Lo Sasso G, Huzard D, Aebischer P, Sandi C, Rinsch C, Auwerx J. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nat Med. 2016 Aug;22(8):879-88. doi: 10.1038/nm.4132. Epub 2016 Jul 11.
- Hvid LG, Suetta C, Nielsen JH, Jensen MM, Frandsen U, Ortenblad N, Kjaer M, Aagaard P. Aging impairs the recovery in mechanical muscle function following 4 days of disuse. Exp Gerontol. 2014 Apr;52:1-8. doi: 10.1016/j.exger.2014.01.012. Epub 2014 Jan 18.
- Hajj-Boutros G, Sonjak V, Faust A, Hedge E, Mastrandrea C, Lagace JC, St-Martin P, Naz Divsalar D, Sadeghian F, Chevalier S, Liu-Ambrose T, Blaber AP, Dionne IJ, Duchesne S, Hughson R, Kontulainen S, Theou O, Morais JA. Impact of 14 Days of Bed Rest in Older Adults and an Exercise Countermeasure on Body Composition, Muscle Strength, and Cardiovascular Function: Canadian Space Agency Standard Measures. Gerontology. 2023;69(11):1284-1294. doi: 10.1159/000534063. Epub 2023 Sep 15.
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Начало исследования
Первичное завершение (Оцененный)
Первичное завершение
Завершение исследования (Оцененный)
Завершение исследования
Даты регистрации исследования
Первый отправленный
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Первый опубликованный
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее опубликованное обновление
Последнее отправленное обновление, отвечающее критериям контроля качества
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
Другие идентификационные номера исследования
- 2027-13109
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .